Tex. Gov't Code § 549.0311 · Subchapter G. DRUG UTILIZATION REVIEW BOARD
BOARD SUMMARY OF CERTAIN INFORMATION REQUIRED.
Text — Current through the 89th 2nd Called Legislative Session, 2025
(a) The executive commissioner by rule shall require the board or the board's designee to present a summary of any clinical efficacy and safety information or analyses regarding a drug under consideration for a preferred drug list the commission adopts under Subchapter E that is provided to the board by a private entity that contracted with the commission to provide the information. Confidential information described by Subchapter D must be omitted from the summary.
(b) The board or the board's designee shall provide the summary in electronic form before the public meeting at which consideration of the drug occurs.
(c) The summary must be posted on the commission's Internet website.
Notes and commentary — not statutory text
History
Added by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 1.01, eff. April 1, 2025.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/GV/htm/GV.549.htm
- Text hash
- sha256 ca3f949bc1fbf581d42245857cca5acffb7b42b6183fc74bcf895b02dbc44096
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Cited by 1 provision
Provisions in this library whose text cites Tex. Gov't Code § 549.0311. Each shows the citation as that text prints it.
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.